Work

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Year: 2012

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.2959.2959

Authors: Beata Holkova, Edward B. Perkins, Prithviraj Bose, Daniel M Sullivan, Rachid Baz, Mary Beth Tombes, Ellen Shrader, Viswanathan Ramakrishnan, Wen Wan, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Steven Grant

Institutions: VCU Massey Comprehensive Cancer Center, Moffitt Cancer Center, Medical University of South Carolina, Yale University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2582885441

FWCI: 0.415

Cites:

Cited by: 3

Related to: 10